RELATIONSHIP BETWEEN RENAL-FUNCTION AND DISPOSITION OF ORAL CEFIXIME

被引:9
作者
DHIB, M [1 ]
MOULIN, B [1 ]
LEROY, A [1 ]
HAMEAU, B [1 ]
GODIN, M [1 ]
JOHANNIDES, R [1 ]
FILLASTRE, JP [1 ]
机构
[1] CHU ROUEN, HOP BOIS GUILLAUME, DEPT NEPHROL, F-76230 BOIS GUILLAUME, FRANCE
关键词
CEFIXIME; RENAL FAILURE; PHARMACOKINETICS; VOLUNTEERS; ADVERSE EFFECTS;
D O I
10.1007/BF00314988
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of cefixime following a single oral dose of 200 mg have been investigated in 6 normal subjects and in 22 patients with various degrees of renal insufficiency. Serum and urine samples were collected between 0 and 72 h and were subjected to two methods of analysis: bioassay and HPLC. There was a linear relationship between the two sets of results from 228 samples. This result suggests that none of the metabolites, which may accumulte in uraemic patients, has antibacterial activity. In normal subjects, the peak serum level (C(max)) was 2.50-mu-g.ml-1 at 2.83 h (t(max)); the apparent elimination half-life (t1/2) was 3.73 h; the apparent total body clearance (CL.f-1) was 154 ml.min-1, the mean renal clearance (CL(R)) was 39.1 ml.min-1 and the apparent fraction of the dose recovered in 24 h urine was 0.22. In uraemic patients, C(max) and t(max) were slightly increased and t1/2 was increased to 12-14 h in patients with an endogenous creatinine clearance below 20 ml.min-1. The apparent volume of distribution was decreased. Apparent total and renal clearances were lower in proportion to the degree of renal insufficiency. Linear relationships were found between CL/f, CL(R) and creatinine clearance (CL(CR)). The findings suggest that the dose of cefixime needs to be reduced only in patients with severe renal failure.
引用
收藏
页码:579 / 583
页数:5
相关论文
共 12 条
[1]  
ARAKAWA S, 1985, CHEMOTHERAPY-TOKYO, V33, P701
[2]  
DEGUCHI K, 1986, CHEMOTHERAPY-TOKYO, V33, P50
[3]   PHARMACOKINETICS OF CEFIXIME IN THE YOUNG AND ELDERLY [J].
FAULKNER, RD ;
BOHAYCHUK, W ;
LANC, RA ;
HAYNES, JD ;
DESJARDINS, RE ;
YACOBI, A ;
SILBER, BM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 21 (06) :787-794
[4]   THE PHARMACOKINETICS OF CEFIXIME IN THE FASTED AND FED STATE [J].
FAULKNER, RD ;
BOHAYCHUK, W ;
HAYNES, JD ;
DESJARDINS, RE ;
YACOBI, A ;
SILBER, BM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (05) :525-528
[5]   ABSOLUTE BIOAVAILABILITY OF CEFIXIME IN MAN [J].
FAULKNER, RD ;
FERNANDEZ, P ;
LAWRENCE, G ;
SIA, LL ;
FALKOWSKI, AJ ;
WEISS, AI ;
YACOBI, A ;
SILBER, BM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (08) :700-706
[6]  
FILLASTRE J P, 1982, Nephrologie, V3, P12
[7]   DRUG-THERAPY - CLINICAL PHARMACOKINETICS .1. [J].
GREENBLATT, DJ ;
KOCHWESER, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 293 (14) :702-705
[8]   PHARMACOKINETICS OF CEFIXIME (CL-284,635, FK-027) IN HEALTHY-SUBJECTS AND PATIENTS WITH RENAL-INSUFFICIENCY [J].
GUAY, DRP ;
MEATHERALL, RC ;
HARDING, GK ;
BROWN, GR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (03) :485-490
[9]   INVITRO AND INVIVO ANTIBACTERIAL PROPERTIES OF FK-027, A NEW ORALLY ACTIVE CEPHEM ANTIBIOTIC [J].
KAMIMURA, T ;
KOJO, H ;
MATSUMOTO, Y ;
MINE, Y ;
GOTO, S ;
KUWAHARA, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (01) :98-104
[10]   COMPARATIVE INVITRO ACTIVITY AND BETA-LACTAMASE STABILITY OF FR-17027, A NEW ORALLY ACTIVE CEPHALOSPORIN [J].
NEU, HC ;
CHIN, NX ;
LABTHAVIKUL, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (02) :174-180